Hypotensive glaucoma therapy and neuroprotection by A. N. Zhuravleva, M. V. Zueva

“…Most modern antihypertensive drugs used in the treatment of primary open-angle glaucoma have an indirect neuroprotective effect not only because they reduce intraocular pressure (IOP), but also because of a stimulating effect on the natural metabolic processes in the eye. …”
Get full text

Fractal Phototherapy in Neuroprotection of Glaucoma by M. V. Zueva, M. A. Kovalevskaya, O. V. Donkareva, A. I. Karankevich, I. V. Tsapenko, A. A. Taranov, V. B. Antonyan

“…Purpose: to study the effect of low-intensity fractal light stimulation on the sensitivity in the visual field in patients with suspected glaucoma (SG) and primary open-angle glaucoma (POAG). …”
Get full text

Risk factors as glaucoma predictors in myopic students by M. A. Kovalevskaya, V. B. Antonyan, E. V. Muntianova, M. V. Zueva

“…FS was shown to contribute to IOP stabilization in patients with pre-existing morphological and functional glaucoma changes and the occurrence of accompanying pathologies such as vasospasm, blood pressure fluctuations, and migraine-like pain. …”
Get full text

Structural and Functional Correlations in Patients with Advanced Stages of Primary Open-Angle Glaucoma by V. I. Kotelin, S. Yu. Petrov, A. N. Zhuravleva, M. V. Zueva, I. V. Tsapenko

“…Purpose: To study the correlations in the diagnosis of patients with advanced stages of primary open-angle glaucoma (POAG) using data from electroretinography and optical coherence tomography (OCT) of the retina.Methods. …”
Get full text

Optimization of Medicinal Treatment of Patients with Glaucoma in Combination with Concurrent System Pathology. Part 1: Cardiovascular Pathology by A. N. Zhuravleva, M. V. Zueva, E. B. Shustov

“…This paper presents clinical and pharmacological drug interactions for the treatment of patients with glaucoma combined with concurrent cardiovascular pathology, risks of side effects, and adverse drug reactions. …”
Get full text

Structural and Functional Disorders in Glaucoma: Prospects for Preclinical Diagnosis. Part 2. Electrophysiological Markers of Early Neuroplastic Events by V. V. Neroev, M. V. Zueva, A. N. Zhuravleva, I. V. Tsapenko

“…The review analyzes the tests of modern electroretinography, which can serve as markers of early events in the development of GON, including plastic changes in the retina at the preclinical stage of glaucoma, and provides physiological rationales for their selective possibilities for clinical practice.…”
Get full text

Structural and Functional Disorders in Glaucoma: the Prospects for Preclinical Diagnosis. Part 1. Is the Search for what Comes First Relevant? by V. V. Neroev, M. V. Zueva, A. N. Zhuravleva, I. V. Tsapenko

“…Progress in understanding the pathogenesis of glaucoma and the expansion of scientific understanding of key risk factors for the development and progression of the disease, including genetic factors, can be crucially important to substantiate new strategies for preclinical diagnosis and the development of radically new approaches to personalized and preventive glaucoma therapy. …”
Get full text

A personalized approach to preclinical diagnosis and initial therapy of primary glaucoma based on a comprehensive structural and functional examination.... by A. N. Zhuravleva, M. V. Zueva, S. Y. Petrov, M. O. Kirillova, S. M. Kosakyan, I. V. Tsapenko

“…The principles of personalized approach to early diagnosis and monitoring of primary glaucoma are shown by a clinical example. We analyzed the potentials of contemporary electrophysiological tests for preclinically diagnosing glaucoma optic neuropathy and monitoring drug treatment. …”
Get full text

Structural and functional correlations in the pre-perimetric and the initial stages of glaucomatous optic neuropathy by M. O. Kirillova, A. N. Zhuravleva, M. V. Zueva, I. V. Tsapenko

“…Two clinical groups: (I) 35 patients (60 eyes) aged 49–70 (ave. 58.0 ± 5.3 yrs) with suspected glaucoma and (II) 21 patients (30 eyes) aged 46-68 (ave. 61.0 ± 4.8 yrs) with initial primary open-angle glaucoma (POAG), and a comparison group consisting of 36 relativelyhealthy subjects (41 eyes) aged 54–70 (ave. 62.0 ± 4.5 yrs), were subjected to spectral OCT by OСT Spectralis (Heidelberg Engineering, Germany). …”
Get full text

Electrophysiological markers of preclinical diagnosis of glaucomatous optic neuropathy by M. O. Kirillova, M. V. Zueva, I. V. Tsapenko, A. N. Zhuravleva

“…Two clinical groups, (1) 35 patients (60 eyes) aged 49 to 70 with suspected glaucoma and (2) 16 patients (30 eyes) aged 43–68 with initial primary open-angle glaucoma (POAG), and a comparison group of 38 relatively healthy subjects (45 eyes) aged 42–70 were tested for pattern-reversed visual evoked potentials (PVEP), transient and stationary pattern-ERGs (PERG) according to ISCEV, and photopic negative response (PhNR).Results. …”
Get full text

Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer’s Disease and a Target of Neuroprotective Therapy by M. V. Zueva, A. N. Zhuravleva, A. N. Bogolepova

“…Irreversible damage to the structure of axons and death of the retinal ganglion cell (RGC) soma in primary open-angle glaucoma (POAG) and Alzheimer’s disease (AD) develop against the background of the already existing clinical manifestation, which is preceded by a slow period of progressive loss of synapses and dendrites of the RGCs. …”
Get full text

Dendritic Branching of Retinal Ganglion Cells as a Biomarker of Glaucomatous Optic Neuropathy and Alzheimer’s Disease and a Target of Neuroprotective Therapy by M. V. Zueva, A. N. Zhuravleva, A. N. Bogolepova

“…Irreversible damage to the structure of axons and death of the retinal ganglion cell (RGC) soma in primary open-angle glaucoma (POAG) and Alzheimer’s disease (AD) develop against the background of the already existing clinical manifestation, which is preceded by a slow period of progressive loss of synapses and dendrites of the RGCs. …”
Get full text

Electrophysiological markers of advanced stages of glaucomatous optic neuropathy by V. I. Kotelin, M. V. Zueva, I. V. Tsapenko, S. Yu. Petrov, A. N. Zhuravleva

“…The study involved 35 patients (55 eyes) aged 51–76 (63.1 ± 7.7 years) with primary open-angle glaucoma (POAG), divided into two subgroups depending on POAG stages: developed (24 patients, 27 eyes) and advanced stages (24 patients, 28 eyes). …”
Get full text